Calcium receptor modulating agents

Details Calcium receptor modulating agents Calcium receptor modulating agents

2007-02-13

2007-02-13

Hartley, Michael G. (Department: 1617)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S444000, C548S503000, C548S509000, C514S410000, C514S411000, C514S412000, C514S415000

Reexamination Certificate

active

10444945

ABSTRACT:
The compounds of the invention are represented by the following general structureor a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

REFERENCES:
patent: 5981599 (1999-11-01), Moe et al.
patent: 6001884 (1999-12-01), Nemeth et al.
patent: 6011068 (2000-01-01), Nemeth et al.
patent: 6031003 (2000-02-01), Nemeth et al.
patent: 6103737 (2000-08-01), Cocuzza et al.
patent: 6172091 (2001-01-01), Cohen et al.
patent: 6225316 (2001-05-01), Bos et al.
patent: 6335338 (2002-01-01), Bhatnagar et al.
patent: 6403832 (2002-06-01), Oikawa et al.
patent: 6407111 (2002-06-01), Bos et al.
patent: 6436152 (2002-08-01), Chassot et al.
patent: 2002/0143212 (2002-10-01), Oikawa et al.
patent: 0 039 051 (1981-11-01), None
patent: 0 933 354 (1999-08-01), None
patent: WO 93/04373 (1993-03-01), None
patent: WO 94/18959 (1994-09-01), None
patent: WO 95/11221 (1995-04-01), None
patent: WO 96/05818 (1996-02-01), None
patent: WO 96/09818 (1996-04-01), None
patent: WO 96/12697 (1996-05-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 97/05252 (1997-02-01), None
patent: WO 97/37967 (1997-10-01), None
patent: WO 97/41090 (1997-11-01), None
patent: WO 98/01417 (1998-01-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 98/45255 (1998-10-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 00/21910 (2000-04-01), None
patent: WO 01/34562 (2001-05-01), None
patent: WO 01/90069 (2001-11-01), None
patent: WO 01/96307 (2001-12-01), None
patent: WO 01/96365 (2001-12-01), None
patent: WO 02/051805 (2002-07-01), None
patent: WO 02/096424 (2002-12-01), None
Nemeth, E. F.; Steffey, L. G.; Jammerland, L. G.; Hung, B. C. P.; Van Wagenen, B. C.; Delmar, E. G.; Balandrin, M. F. Proc. Natl. Acad. Sci. US 1998, 95, 4040-4045.
Singhal, S.; Johnson, C. A.; Udelsman, R. Orthopedics 2001, 24, 1003-1009.
Zaidi, M. Bioscience Reports 1990, 10, 493-507.
Wittig, J. C.; Bickels, J.; Priebat, D.; Jelinek, J.; Kellar-Graney, K.; Shmookler, B.; Malawer, M. M. Am. Family Physician 2002, 65, 1123-1132.
March, J. (1992). Advanced Organic Chemistry: Reactions, Mechanimsms, and Structure (pp. 898-900). Canada: John Wiley & Sons, Inc.
Berge et al., “Pharmaceutical Salts,”J. Pharm. Sci. 66(1):1-19 (1977).
Brown et al., “Neomycin Mimics the Effects of High Extracellular Calcium Concentrations on Parathyroid Function in Dispersed Bovine Parathyroid Cells,”Endocrinology128(6):3047-3054 (1991).
Bundgaard et al., “A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group,”J. Med. Chem., 32(12):2503-2507 (1989).
Chen et al., “The Diltiazem Analog TA-3090 Mimics the Actions of High Extracellular Ca2+on Parathyroid Function in Dispersed Bovine Parathyroid Cells,”J. Bone Miner. Res. 5(6):581-587 (1990).
Dauban et al., “N1-Arylsulfonyl-N2-(1-aryl)ethyl-3-phenylpropane-1,2-diamines as Novel Calcimimetics Acting on the Calcium Sensing Receptor,”Bioorg. Med. Chem. Let. 10(17):2001-2004 (2000).
Garrett et al., “Calcitonin-Secreting Cells of the Thyroid Express an Extracellular Calcium Receptor Gene,”Endocrinology136(11):5202-5211 (1995).
Garrett et al., “Molecular Cloning and Functional Expression of Human Parathyroid Calcium Receptor cDNAs,”J. Biol. Chem. 270(21):12919-12925 (1995).
J. Bone Miner. Res. 9(Supple. 1):S282 (1994).
J. Bone Miner. Res. 9(Supple. 1):S409 (1994).
Kabalka et al., “The Reduction of Azides With Borohydride Supported on an Ion Exchange Resin,”Synth. Commun., 20(2):293-299 (1990).
Nemeth, “Regulation of Cytosolic Calcium by Extracellular Divalent Cations in C-cells and Parathyroid Cells,”Cell Calcium11:323-327 (1990).
Sande et al., “Borohydride Reducing Agent Derived From Anion Exchange Resin: Selective Reduction of α,β-Unsaturated Carbonyl Compounds,”Tetrahedron Lett. 25(32):3501-3504 (1984).
Svensson and Tunek, “The Design and Bioactivation of Presystemically Stable Prodrugs,”Drug Metabolsim Reviews19(2):165-194 (1988).
Zaidi, “Calcium Receptors' on Eukaryotic Cells with Special Reference to the Osteoclast,”Bioscience Reports10(6):493-507 (1990).
Woodruff et al., “Resonance Raman Spectra of Cobalt Myoglobins and Cobalt Porphyrins. Evaluation of Protein Effects on Porphyrin Structure,”J. Am. Chem. Soc. 97(7):1695-1700 (1975).
U.S. Appl. No. 10/444,946, filed May 22, 2003, Kelly et al.
Nemeth et al. (1998), “Calcimimetics with potent and selective activity on the parathyroid calcium receptor,”Proc. Natl. Acad. Sci. USA95:4040-4045.

Affiliated with

Also associated with

Rating

Calcium receptor modulating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Calcium receptor modulating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium receptor modulating agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3894585